App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)

• DOI: 10.1093/nop/npae002
• Publication Date: 2024-01-21T01:30:13Z
• Authors: Lorenz Dörner; Lucia Grosse; Felix Stange; Hanni Hille; Sylvia Kurz; Hannes Becker; Sebastian Volkmer; Melina Hippler; David Rieger; Paula Bombach; Johannes Rieger; Lina Weinert; Laura Svensson; Carolin Anders; Sila Cekin; Frank Paulsen; Öznur Öner; Kristina Ruhm; Holly Sundberg Malek; Yonne Möller; Marcos Tatagiba; Markus Wallwiener; Nils Eckert; Pascal Escher; Nico Pfeifer; Andrea Forschner; Armin Bauer; Daniel Zips; Michael Bitzer; Nisar Malek; Cihan Gani; Ghazaleh Tabatabai; Mirjam Renovanz
• Keywords: Personalized Medicine; TRACE (psycholinguistics); Center (category theory)

Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients' perspectives during biomarker-based into consideration. We assessed the feasibility an electronic PRO via a smartphone application. An interdisciplinary expert panel developed application based on symptom burden and health-related quality life (HRQoL) metrics reported retrospective analysis 292 neuro-oncological patients. The app included validated assessments (HRQoL), symptoms, psychological stress. Feasibility usability were tested pilot study. Semi-structured interviews with health care professionals (HCP) conducted, transcribed, analyzed according Mayring´s qualitative content analysis. Furthermore, we compliance descriptive data ePROs. A total 14 have been enrolled, (9 female, 5 male). 4 HCPs, 9 patients, 1 caregiver interviewed regarding usability/feasibility. main advantages possibility complete questionnaires at home comfortable implementation daily life. Compliance was high, for example, 82% weekly distributed NCCN distress thermometer answered time, however, interindividual variability. observed median score (range 0-10, 197 results, n = 12, assessed) Global 58.3 EORTC QLQ-C30 instrument 16.7-100, 77 monthly assessed). This study proved acceptance app. will therefore expand its biomarker-guided enable systematic assessments.